OBJECTIVE: The authors investigated the relationship between number of lifetime episodes of affective disorder and the antimanic response to lithium, divalproex, or placebo. METHOD: The subjects were 154 of the 179 inpatients with acute mania who entered a 3-week parallel group, double-blind study. The primary efficacy measure was the manic syndrome score from the Schedule for Affective Disorders and Schizophrenia. The relationship between improvement and number of previous episodes was investigated by using nonlinear regression analysis. RESULTS: An apparent transition in the relationship between number of previous episodes and response to antimanic medication occurred at about 10 previous episodes. For patients who had experienced more episodes, response to lithium resembled the response to placebo but was worse than response to divalproex. For patients who had experienced fewer episodes, however, the responses to lithium and divalproex did not differ and were better than the response to placebo. This differential response pattern was not related to rapid cycling or mixed states. CONCLUSIONS: A history of many previous episodes was associated with poor response to lithium or placebo but not to divalproex.
RCT Entities:
OBJECTIVE: The authors investigated the relationship between number of lifetime episodes of affective disorder and the antimanic response to lithium, divalproex, or placebo. METHOD: The subjects were 154 of the 179 inpatients with acute mania who entered a 3-week parallel group, double-blind study. The primary efficacy measure was the manic syndrome score from the Schedule for Affective Disorders and Schizophrenia. The relationship between improvement and number of previous episodes was investigated by using nonlinear regression analysis. RESULTS: An apparent transition in the relationship between number of previous episodes and response to antimanic medication occurred at about 10 previous episodes. For patients who had experienced more episodes, response to lithium resembled the response to placebo but was worse than response to divalproex. For patients who had experienced fewer episodes, however, the responses to lithium and divalproex did not differ and were better than the response to placebo. This differential response pattern was not related to rapid cycling or mixed states. CONCLUSIONS: A history of many previous episodes was associated with poor response to lithium or placebo but not to divalproex.
Authors: Michael Berk; Lesley Berk; Seetal Dodd; Sue Cotton; Craig Macneil; Rothanthi Daglas; Philippe Conus; Andreas Bechdolf; Steven Moylan; Gin S Malhi Journal: Bipolar Disord Date: 2013-06-20 Impact factor: 6.744
Authors: L Lavagnino; B Cao; B Mwangi; M-J Wu; M Sanches; G B Zunta-Soares; F Kapczinski; J Soares Journal: Acta Psychiatr Scand Date: 2015-01-31 Impact factor: 6.392
Authors: Ana Cristina Andreazza; Flavio Kapczinski; Marcia Kauer-Sant'Anna; Julio C Walz; David J Bond; Carlos A Gonçalves; L Trevor Young; Lakshmi N Yatham Journal: J Psychiatry Neurosci Date: 2009-07 Impact factor: 6.186
Authors: Michael Berk; Robert Post; Aswin Ratheesh; Emma Gliddon; Ajeet Singh; Eduard Vieta; Andre F Carvalho; Melanie M Ashton; Lesley Berk; Susan M Cotton; Patrick D McGorry; Brisa S Fernandes; Lakshmi N Yatham; Seetal Dodd Journal: World Psychiatry Date: 2017-10 Impact factor: 49.548
Authors: Troy Bremer; Cornelius Diamond; Rebecca McKinney; Tatyana Shehktman; Thomas B Barrett; Chris Herold; John R Kelsoe Journal: Mol Diagn Ther Date: 2007 Impact factor: 4.074